



Worldwide strategic alliance between IngenBio Corporation and Harcos Inc.

CONTACT: Dr. Harlan Griffin – August 8, 2008

/PRNNewswire/ --IngenBio Corporation and Harcos Pharmaceuticals today announced a worldwide strategic alliance to develop and market antibody nutraceuticals which target cancer cells as well as other life threatening diseases. The alliance with IngenBio will be conducted through its revolutionary "INTRAGEN®" program.

The alliance leverages IngenBio's expertise in the discovery and development of cancer cell antibody therapeutics and provides Harcos with the ability to directly market Intragen® to consumers.

Harcos has established a diverse pipeline of nutraceutical distribution in North America. The alliance focuses on IngenBio's lead antibody product, Intragen®, a recombinant (genetically engineered) protein that stimulates the production of infection-fighting white blood cells that are depleted by cytotoxic chemotherapy, a condition called neutropenia.

In the alliance, Harcos will utilize its proprietary containment enclosures to protect and transport monoclonal antibodies in specific nutraceutical package, initially for an undisclosed control group, a first step towards mass distribution. Using IngenBio's Intragen® Longitudinal Cancer Research (LCR), IngenBio will identify, segment, and target white blood cell mutation through detailed analysis of mutation patterns and patient populations.

"This alliance places IngenBio as the world leader in the development of oncology medicines and provides us worldwide access to an exciting new marketplace of drug discovery." said Dr. Harlan Griffin, President and head of IngenBio Corporation. "This partnership ensures that we develop potential therapeutics in a manner that will address unmet medical needs and meet the changing demands of the marketplace. We strive to integrate the perspectives from military research, clinical development and infectious disease research into all of our drug development programs."

"We believe this partnership has the potential to change the way consumers are treated and we are very excited to be working with Harcos to develop innovative medicines in this regard," said Dr. Griffin.

"We are extremely pleased to collaborate with IngenBio given their proven commitment to innovation and their expertise in the development and commercialization of oncology medicines," said Elijah Szasz, President and CEO of Harcos Inc. "This strategic alliance," adds Biomedical Industry Liaison Aaron Rasmussen "provides important support of our scientific expertise in the field of nutraceutical development."

Rare events of adult immune distress syndrome, lymphatic rupture, and neural crises have been reported in postmarketing experience in patients receiving INTRAGEN®.

For more information on Ingen Bio: www.ingenbio.com
For more information on Harcos Inc. www.harcos-inc.com